266 related articles for article (PubMed ID: 32974856)
21. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
Cheuk DK; Chiang AK; Chan GC; Ha SY
Cochrane Database Syst Rev; 2014 Aug; (8):CD006945. PubMed ID: 25121561
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.
Feng X; Dong K; Pham D; Pence S; Inciardi J; Bhutada NS
J Clin Pharm Ther; 2013 Aug; 38(4):301-8. PubMed ID: 23550846
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
Hu S; Han Y; Zhang W; Zhang T; Yao X; Liu L
J Med Econ; 2019 Aug; 22(8):742-750. PubMed ID: 30939962
[No Abstract] [Full Text] [Related]
24. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients.
Annemans L; Moeremans K; Lamotte M; Garcia Conde J; van den Berg H; Myint H; Pieters R; Uyttebroeck A
Support Care Cancer; 2003 Apr; 11(4):249-57. PubMed ID: 12673464
[TBL] [Abstract][Full Text] [Related]
25. Treatment of tumor lysis syndrome in children with leukemia/lymphoma in resource-limited settings-Efficacy of a fixed low-dose rasburicase.
Gopakumar KG; Thankamony P; Seetharam S; P K
Pediatr Hematol Oncol; 2017 May; 34(4):206-211. PubMed ID: 28872997
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of rasburicase (recombinant urate oxidase) in the prevention and treatment of malignancy-associated hyperuricemia: an Indian experience.
Digumarti R; Sinha S; Nirni SS; Patil SG; Pedapenki RM
Indian J Cancer; 2014; 51(2):180-3. PubMed ID: 25104205
[TBL] [Abstract][Full Text] [Related]
27. Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach.
Campara M; Shord SS; Haaf CM
J Clin Pharm Ther; 2009 Apr; 34(2):207-13. PubMed ID: 19250141
[TBL] [Abstract][Full Text] [Related]
28. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
Goldman SC; Holcenberg JS; Finklestein JZ; Hutchinson R; Kreissman S; Johnson FL; Tou C; Harvey E; Morris E; Cairo MS
Blood; 2001 May; 97(10):2998-3003. PubMed ID: 11342423
[TBL] [Abstract][Full Text] [Related]
29. [Pharmacological and clinical profile of rasburicase (Rasuritek)].
Ohno K; Tawara K
Nihon Yakurigaku Zasshi; 2010 Jun; 135(6):255-60. PubMed ID: 20543517
[No Abstract] [Full Text] [Related]
30. Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies.
Wang LY; Shih LY; Chang H; Jou ST; Lin KH; Yeh TC; Lin SF; Liang DC
Acta Haematol; 2006; 115(1-2):35-8. PubMed ID: 16424647
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
Coiffier B; Mounier N; Bologna S; Fermé C; Tilly H; Sonet A; Christian B; Casasnovas O; Jourdan E; Belhadj K; Herbrecht R;
J Clin Oncol; 2003 Dec; 21(23):4402-6. PubMed ID: 14581437
[TBL] [Abstract][Full Text] [Related]
32. [Rasburicase versus allopurinol in the treatment of hyperuricaemia in tumour lysis syndrome].
Tatay VS; Castilla JD; Ponce JM; Hurtado JM; Cantero E; Abril ML
An Pediatr (Barc); 2010 Feb; 72(2):103-10. PubMed ID: 20022572
[TBL] [Abstract][Full Text] [Related]
33. Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report.
Galardy PJ; Hochberg J; Perkins SL; Harrison L; Goldman S; Cairo MS
Br J Haematol; 2013 Nov; 163(3):365-72. PubMed ID: 24032600
[TBL] [Abstract][Full Text] [Related]
34. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
Bosly A; Sonet A; Pinkerton CR; McCowage G; Bron D; Sanz MA; Van den Berg H
Cancer; 2003 Sep; 98(5):1048-54. PubMed ID: 12942574
[TBL] [Abstract][Full Text] [Related]
35. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.
McDonnell AM; Lenz KL; Frei-Lahr DA; Hayslip J; Hall PD
Pharmacotherapy; 2006 Jun; 26(6):806-12. PubMed ID: 16716134
[TBL] [Abstract][Full Text] [Related]
36. The value of fixed rasburicase dosing versus weight-based dosing in the treatment and prevention of tumor lysis syndrome.
Boutin A; Blackman A; O'Sullivan DM; Forcello N
J Oncol Pharm Pract; 2019 Apr; 25(3):577-583. PubMed ID: 29320954
[TBL] [Abstract][Full Text] [Related]
37. Rasburicase: a review of its use in the management of anticancer therapy-induced hyperuricaemia.
Oldfield V; Perry CM
Drugs; 2006; 66(4):529-45. PubMed ID: 16597166
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of recombinant urate oxidase (rasburicase) for treatment and prophylaxis of hyperuricemia in children undergoing chemotherapy.
Pession A; Barbieri E; Santoro N; Paolucci P; Porta F; Locatelli F
Haematologica; 2005 Jan; 90(1):141-2. PubMed ID: 15642687
[TBL] [Abstract][Full Text] [Related]
39. Clarifying the role of rasburicase in tumor lysis syndrome.
Sood AR; Burry LD; Cheng DK
Pharmacotherapy; 2007 Jan; 27(1):111-21. PubMed ID: 17192165
[TBL] [Abstract][Full Text] [Related]
40. Fixed-Dose Recombinant Urate Oxidase in the Treatment of Paediatric Tumour Lysis Syndrome: A Regional Cancer Centre Experience.
L A; Reddy JM; Chebbi PG; Kumar N; Ar AK; M P; B S AK
Asian Pac J Cancer Prev; 2021 Dec; 22(12):3897-3901. PubMed ID: 34967569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
